Can anyone here comment on HGSI's intellectual property position on anti-TRAILR antibodies? In my opinion anti-TRAILR antibodies are a promising strategy for cancer. Both AMGN and DNA have anti-TRAILR antibodies in clinical trials (in addition to a recombinant TRAIL protein--I think the antibody approach is better). In addition, academic researchers @UAB have identified the TRA-8 antibody (anti-DR5). IMO multiple groups coming to the same conclusions further validates the anti-TRAILR approach. HGSI has the most advanced clinical development. Based on my readings, HGSI looks like they have a strong/dominant IP position on anti-TRAILR antibodies. Is HGSI's IP position strong enough to prevent other anti-TRAILR antibodies from coming to market?
Comments appreciated,
biophud
11:55AM Human Genome reports growing evidence that tts TRAIL Receptor Antibodies have significant potential in the treatment of a broad range of cancers (HGSI) 11.29 +0.00 : Co reported that clinical and preclinical evidence continues to emerge demonstrating that its TRAIL receptor antibodies, HGS-ETR1 (mapatumumab) and HGS-ETR2 (lexatumumab), have significant potential for use in the treatment of a broad range of cancers. "We believe that HGS-ETR1 and HGS-ETR2 could offer novel, highly targeted therapeutic options that may prove useful in the treatment of a number of cancers," said Gilles Gallant, B. Pharm., Ph.D., Vice President, Clinical Research - Oncology, HGSI. "We note with pride that the Journal of Clinical Oncology, one of the field's most prestigious peer-reviewed publications, chose to publish the first human study of HGS-ETR1 earlier this month with an accompanying editorial - and, last week at AACR 2007, approximately 1500 cancer scientists and researchers attended our oral presentation of research results to date."
